Drug Trial Radar · NCT02858310
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
224
Actual
Start
Jan 27, 2017
Primary completion
Jul 2, 2025
Study completion Jul 2, 2025
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Aug 8, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells. In this new therapy, researchers take a person's blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the E7 protein. The genetically changed cells, called E7 T cell receptor (TCR) cells, are then given back to the person to fight the cancer. Researchers want to see if this can help people. Objective: To determine a safe dose and efficacy of E7 TCR cells and whether these cells can help patients. Eligibility: Adults ages 18 and older with an HPV-16-associated cancer, including cervical, vulvar, vaginal, penile, anal, or oropharyngeal. Design: Participants will list all their medicines. Participants will have many screening tests, including imaging procedures, heart and lung tests, and lab tests. They will have a large catheter inserted into a vein. Participants will have leukapheresis. Blood will be removed through a needle in the arm. A machine separates the white blood cells. The rest of the blood is returned through a needle in the other arm. The cells will be changed in the lab. Participants will stay in the hospital. Over several days, they will get: Chemotherapy drugs E7 TCR cells Shots or injections to stimulate the cells Participants will be monitored in the hospital up to 12 days. They will get support medicine and have blood and lab tests. Participants will have a clinic visit about 40 days after cell infusion. They will have a physical exam, blood work, scans, and maybe x-rays. Participants will have many follow-up visits with the same procedures. At some visits, they may undergo leukapheresis. Participants will be followed for 15 years.
Conditions
- Papillomavirus Infections
- Cervical Intraepithelial Neoplasia
- Carcinoma In Situ
- Vulvar Neoplasms
- Vulvar Diseases
Interventions
E7 TCR cellsBiological
T cells genetically engineered with a T cell receptor (TCR) targeting human papillomavirus (HPV -16 E7 (E7 TCR) that display specific reactivity against human leukocyte antigen (HLA-A2+, HPV-16+ target cells.
AldesleukinDrug
Following cell infusion, the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 T cell receptor (TCR) cells after infusion.
FludarabineDrug
Part of the non-myeloablative lymphocyte-depleting preparative regimen.
CyclophosphamideDrug
Part of the non-myeloablative lymphocyte-depleting preparative regimen.
EKGDiagnostic test
Screening/Baseline. Follow-up (end of treatment).
BiopsyProcedure
Screening/Baseline. Following treatment (6 weeks post treatment preferred) and at disease progression only.
Chest CT and MRI or PETDiagnostic test
Screening/Baseline. Follow-up (end of treatment). 40 days (+/- 2 weeks) after cell infusion; additional visits as indicated.
PFTDiagnostic test
Screening/Baseline.
GranisetronDrug
Supportive medication for nausea/vomiting/anorexia. 0.01 mg/kg intravenous (IV) every(q) day as needed (prn).
OndansetronDrug
Supportive medication for nausea/vomiting/anorexia. Ondansetron 10mg intravenous (IV) every(q) 8 hours(hr) as needed (prn).
DroperidolDrug
Supportive medication for nausea/vomiting/anorexia. 1mg intravenous (IV) at 4-6 hours(h) as needed (prn).
ProchlorperazineDrug
Supportive medication for nausea/vomiting/anorexia. 25mg per rectum (PR) as needed (prn) or 10mg intravenous (IV) every(q) 6hours(h) prn.
Diphenoxylate HCLDrug
Supportive medication for diarrhea. 2.5mg by mouth (po) every(q) 3 hours(h) as needed (prn).
Atropine sulfateDrug
Supportive medication for diarrhea. 25mcg by mouth (po) every(q) 3 hours(h) as needed (prn).
Codeine sulfateDrug
Supportive medication for diarrhea. 30-60mg by mouth (po) every(q) 4 hours(h) as needed (prn).
LoperamideDrug
Supportive medication for diarrhea. 2mg by mouth (po) every(q) 3 hours(h) as needed (prn).
IndomethacinDrug
Supportive medication for fever. 50-75mg by mouth (po) every(q) 8 hours(h).
AcetaminophenDrug
Supportive medication for fever. 650mg by mouth (po) every 4 hours (q) 4hr.
Diphenhydramine HCLDrug
Supportive medication for pruritis. 25-50mg by mouth (po) every 4 hours (q) 4hr as needed (prn).
Hydroxyzine HCLDrug
Supportive medication for pruritis. 10-20mg by mouth (po) every 6 hours(h), as needed (prn).
MeperidineDrug
Supportive medication for chills. 25-50mg intravenous (IV) every 1 hour (q1hr), as needed (prn).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR)Time frame: At 12 weeks, every 3 months x 3, and every 6 months for approximately 5 years
- Phase I: Number of Dose Limiting Toxicities (DLT)Time frame: From the day of cell infusion (Day 0) to Day +30
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.